|Bid||34.220 x 10800|
|Ask||34.230 x 600|
|Day's Range||33.920 - 34.395|
|52 Week Range||29.830 - 37.390|
|PE Ratio (TTM)||28.94|
|Dividend & Yield||1.28 (3.81%)|
|1y Target Est||N/A|
Morgan Stanley analyst David Risinger argued for the drugmaker to part ways with its consumer health division.
The main thrust of the order appears to be easing regulatory hurdles to drug approvals, which could lower the cost of bringing new treatments to market and thus lower prices.
Back in November, reports circulated that Pfizer (PFE) was considering selling its consumer business. Then...nothing. Now Morgan Stanley analyst David Risinger and team are out with a note calling for ...